1
|
Leslie AR, Ning S, Armstrong CM, D’Abronzo LS, Sharifi M, Schaaf ZA, Lou W, Liu C, Evans CP, Lombard AP, Gao AC. IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience 2024; 27:108984. [PMID: 38327800 PMCID: PMC10847745 DOI: 10.1016/j.isci.2024.108984] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 11/07/2023] [Accepted: 01/17/2024] [Indexed: 02/09/2024] Open
Abstract
Olaparib is a pioneering PARP inhibitor (PARPi) approved for treating castration-resistant prostate cancer (CRPC) tumors harboring DNA repair defects, but clinical resistance has been documented. To study acquired resistance, we developed Olaparib-resistant (OlapR) cell lines through chronic Olaparib treatment of LNCaP and C4-2B cell lines. Here, we found that IGFBP3 is highly expressed in acquired (OlapR) and intrinsic (Rv1) models of Olaparib resistance. We show that IGFBP3 expression promotes Olaparib resistance by enhancing DNA repair capacity through activation of EGFR and DNA-PKcs. IGFBP3 depletion enhances efficacy of Olaparib by promoting DNA damage accumulation and subsequently, cell death in resistant models. Mechanistically, we show that silencing IGFBP3 or EGFR expression reduces cell viability and resensitizes OlapR cells to Olaparib treatment. Inhibition of EGFR by Gefitinib suppressed growth of OlapR cells and improved Olaparib sensitivity, thereby phenocopying IGFBP3 inhibition. Collectively, our results highlight IGFBP3 and EGFR as critical mediators of Olaparib resistance.
Collapse
Affiliation(s)
- Amy R. Leslie
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Shu Ning
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | | | | | - Masuda Sharifi
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Zachary A. Schaaf
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Wei Lou
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Chengfei Liu
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA
| | - Christopher P. Evans
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA
| | - Alan P. Lombard
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
- Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, CA, USA
| | - Allen C. Gao
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA
- VA Northern California Health Care System, Sacramento, CA, USA
| |
Collapse
|
2
|
Schaaf ZA, Ning S, Leslie AR, Sharifi M, Han X, Armstrong C, Lou W, Lombard AP, Liu C, Gao AC. Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer. Cancers (Basel) 2023; 15:5273. [PMID: 37958444 PMCID: PMC10650051 DOI: 10.3390/cancers15215273] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 10/31/2023] [Accepted: 11/01/2023] [Indexed: 11/15/2023] Open
Abstract
Current common treatments for castration-resistant prostate cancer (CRPC) typically belong to one of three major categories: next-generation anti-androgen therapies (NGAT) including enzalutamide, abiraterone acetate, apalutamide, and darolutamide; taxane therapy represented by docetaxel; and PARP inhibitors (PARPi) like olaparib. Although these treatments have shown efficacy and have improved outcomes for many patients, some do not survive due to the emergence of therapeutic resistance. The clinical landscape is further complicated by limited knowledge about how the sequence of treatments impacts the development of therapeutic cross-resistance in CRPC. We have developed multiple CRPC models of acquired therapeutic resistance cell sublines from C4-2B cells. These include C4-2B MDVR, C4-2B AbiR, C4-2B ApaR, C4-2B DaroR, TaxR, and 2B-olapR, which are resistant to enzalutamide, abiraterone, apalutamide, darolutamide, docetaxel, and olaparib, respectively. These models are instrumental for analyzing gene expression and assessing responses to various treatments. Our findings reveal distinct cross-resistance characteristics among NGAT-resistant cell sublines. Specifically, resistance to enzalutamide induces resistance to abiraterone and vice versa, while maintaining sensitivity to taxanes and olaparib. Conversely, cells with acquired resistance to docetaxel exhibit cross-resistance to both cabazitaxel and olaparib but retain sensitivity to NGATs like enzalutamide and abiraterone. OlapR cells, significantly resistant to olaparib compared to parental cells, are still responsive to NGATs and docetaxel. Moreover, OlapR models display cross-resistance to other clinically relevant PARP inhibitors, including rucaparib, niraparib, and talazoparib. RNA-sequencing analyses have revealed a complex network of altered gene expressions that influence signaling pathways, energy metabolism, and apoptotic signaling, pivotal to cancer's evolution and progression. The data indicate that resistance mechanisms are distinct among different drug classes. Notably, NGAT-resistant sublines exhibited a significant downregulation of androgen-regulated genes, contrasting to the stable expression noted in olaparib and docetaxel-resistant sublines. These results may have clinical implications by showing that treatments of one class can be sequenced with those from another class, but caution should be taken when sequencing drugs of the same class.
Collapse
Affiliation(s)
- Zachary A. Schaaf
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
| | - Shu Ning
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
| | - Amy R. Leslie
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
| | - Masuda Sharifi
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
| | - Xianrui Han
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
| | - Cameron Armstrong
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
| | - Wei Lou
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
| | - Alan P. Lombard
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
- UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA
- Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95616, USA
| | - Chengfei Liu
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
- UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA
| | - Allen C. Gao
- Department of Urologic Surgery, University of California Davis, Sacramento, CA 95817, USA; (Z.A.S.); (S.N.); (A.R.L.); (M.S.); (X.H.); (C.A.); (W.L.); (A.P.L.); (C.L.)
- UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA 95817, USA
- VA Northern California Health Care System, Sacramento, CA 95655, USA
| |
Collapse
|
3
|
D’Abronzo LS, Lombard AP, Ning S, Armstong CM, Leslie AR, Sharifi M, Schaaf ZA, Lou W, Gao AC. Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer. Am J Clin Exp Urol 2022; 10:299-310. [PMID: 36313205 PMCID: PMC9605943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Accepted: 09/01/2022] [Indexed: 06/16/2023]
Abstract
Resistance to androgen receptor (AR) targeted therapies remains as the main reason for most prostate cancer related deaths. Lineage plasticity resulting in altered, treatment insensitive prostate tumor cell phenotypes such neuroendocrine differentiated prostate cancer is a common manifestation within resistant tumors upon AR-targeted therapies. The mechanisms responsible for lineage plasticity in prostate cancer remain incompletely understood. Here we demonstrate that the enzalutamide resistant MDVR cell line possesses lineage plastic characteristics associated with overexpression of the Wnt transporter Wntless (WLS). Furthermore, we present evidence that overexpression of WLS is common in varying cell line models of lineage plastic prostate cancer, is higher in neuroendocrine patient samples, and positively correlates with the neuroendocrine marker SYP in clinical data. Targeting WLS in lineage plastic cellular models reduces viability and represses lineage plasticity associated gene expression. Our study provides insight into the importance of WLS to the development of lethal resistant prostate cancer and provides a potential target for the treatment of advanced disease.
Collapse
Affiliation(s)
- Leandro S D’Abronzo
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
| | - Alan P Lombard
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
- UC Davis Comprehensive Cancer Center, University of California DavisSacramento, California, USA
- Department of Biochemistry and Molecular Medicine, University of California DavisSacramento, California, USA
| | - Shu Ning
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
| | - Cameron M Armstong
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
| | - Amy R Leslie
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
| | - Masuda Sharifi
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
| | - Zachary A Schaaf
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
| | - Wei Lou
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
| | - Allen C Gao
- Department of Urologic Surgery, University of California DavisSacramento, California, USA
- UC Davis Comprehensive Cancer Center, University of California DavisSacramento, California, USA
- VA Northern California Health Care SystemSacramento, California, USA
| |
Collapse
|
4
|
Ning S, Liu C, Lou W, Yang JC, Lombard AP, D'Abronzo LS, Batra N, Yu AM, Leslie AR, Sharifi M, Evans CP, Gao AC. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Mol Cancer Ther 2022; 21:1594-1607. [PMID: 35930737 PMCID: PMC9547958 DOI: 10.1158/1535-7163.mct-22-0216] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 05/23/2022] [Accepted: 07/28/2022] [Indexed: 01/21/2023]
Abstract
The next-generation antiandrogen drugs such as enzalutamide and abiraterone extend survival times and improve quality of life in patients with advanced prostate cancer. However, resistance to both drugs occurs frequently through mechanisms that are incompletely understood. Wnt signaling, particularly through Wnt5a, plays vital roles in promoting prostate cancer progression and induction of resistance to enzalutamide and abiraterone. Development of novel strategies targeting Wnt5a to overcome resistance is an urgent need. In this study, we demonstrated that Wnt5a/FZD2-mediated noncanonical Wnt pathway is overexpressed in enzalutamide-resistant prostate cancer. In patient databases, both the levels of Wnt5a and FZD2 expression are upregulated upon the development of enzalutamide resistance and correlate with higher Gleason score, biochemical recurrence, and metastatic status, and with shortened disease-free survival duration. Blocking Wnt5a/FZD2 signal transduction not only diminished the activation of noncanonical Wnt signaling pathway, but also suppressed the constitutively activated androgen receptor (AR) and AR variants. Furthermore, we developed a novel bioengineered BERA-Wnt5a siRNA construct and demonstrated that inhibition of Wnt5a expression by the BERA-Wnt5a siRNA significantly suppressed tumor growth and enhanced enzalutamide treatment in vivo. These results indicate that Wnt5a/FZD2 signal pathway plays a critical role in promoting enzalutamide resistance, and targeting this pathway by BERA-Wnt5a siRNA can be developed as a potential therapy to treat advanced prostate cancer.
Collapse
Affiliation(s)
- Shu Ning
- Department of Urologic Surgery, University of California Davis, Davis, California
| | - Chengfei Liu
- Department of Urologic Surgery, University of California Davis, Davis, California
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California
| | - Wei Lou
- Department of Urologic Surgery, University of California Davis, Davis, California
| | - Joy C Yang
- Department of Urologic Surgery, University of California Davis, Davis, California
| | - Alan P Lombard
- Department of Urologic Surgery, University of California Davis, Davis, California
| | - Leandro S D'Abronzo
- Department of Urologic Surgery, University of California Davis, Davis, California
| | - Neelu Batra
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California
- Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, California
| | - Ai-Ming Yu
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California
- Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, California
| | - Amy R Leslie
- Department of Urologic Surgery, University of California Davis, Davis, California
| | - Masuda Sharifi
- Department of Urologic Surgery, University of California Davis, Davis, California
| | - Christopher P Evans
- Department of Urologic Surgery, University of California Davis, Davis, California
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California
| | - Allen C Gao
- Department of Urologic Surgery, University of California Davis, Davis, California
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California
- VA Northern California Health Care System, Sacramento, California
| |
Collapse
|
5
|
Ning S, Zhao J, Lombard AP, D’Abronzo LS, Leslie AR, Sharifi M, Lou W, Liu C, Yang JC, Evans CP, Corey E, Chen HW, Yu A, Ghosh PM, Gao AC. Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes. Commun Med (Lond) 2022; 2:118. [PMID: 36159187 PMCID: PMC9492734 DOI: 10.1038/s43856-022-00182-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2022] [Accepted: 09/05/2022] [Indexed: 01/26/2023] Open
Abstract
Background Treatment-emergent neuroendocrine prostate cancer (NEPC) after androgen receptor (AR) targeted therapies is an aggressive variant of prostate cancer with an unfavorable prognosis. The underlying mechanisms for early neuroendocrine differentiation are poorly defined and diagnostic and prognostic biomarkers are needed. Methods We performed transcriptomic analysis on the enzalutamide-resistant prostate cancer cell line C4-2B MDVR and NEPC patient databases to identify neural lineage signature (NLS) genes. Correlation of NLS genes with clinicopathologic features was determined. Cell viability was determined in C4-2B MDVR and H660 cells after knocking down ARHGEF2 using siRNA. Organoid viability of patient-derived xenografts was measured after knocking down ARHGEF2. Results We identify a 95-gene NLS representing the molecular landscape of neural precursor cell proliferation, embryonic stem cell pluripotency, and neural stem cell differentiation, which may indicate an early or intermediate stage of neuroendocrine differentiation. These NLS genes positively correlate with conventional neuroendocrine markers such as chromogranin and synaptophysin, and negatively correlate with AR and AR target genes in advanced prostate cancer. Differentially expressed NLS genes stratify small-cell NEPC from prostate adenocarcinoma, which are closely associated with clinicopathologic features such as Gleason Score and metastasis status. Higher ARGHEF2, LHX2, and EPHB2 levels among the 95 NLS genes correlate with a shortened survival time in NEPC patients. Furthermore, downregulation of ARHGEF2 gene expression suppresses cell viability and markers of neuroendocrine differentiation in enzalutamide-resistant and neuroendocrine cells. Conclusions The 95 neural lineage gene signatures capture an early molecular shift toward neuroendocrine differentiation, which could stratify advanced prostate cancer patients to optimize clinical treatment and serve as a source of potential therapeutic targets in advanced prostate cancer.
Collapse
Affiliation(s)
- Shu Ning
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA
| | - Jinge Zhao
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA ,grid.13291.380000 0001 0807 1581Present Address: Department of Urology, West China Hospital, Sichuan University, Sichuan, China
| | - Alan P. Lombard
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA
| | - Leandro S. D’Abronzo
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA
| | - Amy R. Leslie
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA
| | - Masuda Sharifi
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA
| | - Wei Lou
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA
| | - Chengfei Liu
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA ,grid.27860.3b0000 0004 1936 9684UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA USA
| | - Joy C. Yang
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA
| | - Christopher P. Evans
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA ,grid.27860.3b0000 0004 1936 9684UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA USA
| | - Eva Corey
- grid.34477.330000000122986657Department of Urology, University of Washington, Seattle, WA USA
| | - Hong-Wu Chen
- grid.27860.3b0000 0004 1936 9684UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA USA ,grid.27860.3b0000 0004 1936 9684Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA USA
| | - Aiming Yu
- grid.27860.3b0000 0004 1936 9684UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA USA ,grid.27860.3b0000 0004 1936 9684Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA USA
| | - Paramita M. Ghosh
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA ,grid.27860.3b0000 0004 1936 9684UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA USA ,grid.27860.3b0000 0004 1936 9684Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA USA ,grid.413933.f0000 0004 0419 2847VA Northern California Health Care System, Sacramento, CA USA
| | - Allen C. Gao
- grid.27860.3b0000 0004 1936 9684Department of Urologic Surgery, University of California Davis, Sacramento, CA USA ,grid.27860.3b0000 0004 1936 9684UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA USA ,grid.413933.f0000 0004 0419 2847VA Northern California Health Care System, Sacramento, CA USA
| |
Collapse
|
6
|
Lombard AP, Lou W, Evans CP, Gao AC. Abstract 1850: Characterizing senescence response to PARP inhibition may provide opportunities for enhanced efficacy through combinations with senolytic agents. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-1850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inhibition of poly (ADP-ribose) polymerase (PARP) is an exciting treatment strategy recently approved for prostate cancer patients with homologous recombination repair defects. Despite this advance in the field, it remains unclear how PARP inhibitor (PARPi) sensitive cells respond to treatment. We previously demonstrated that treatment with the PARPi olaparib induces not only cell death, but also G2/M arrested senescence characterized by activation of the p53 signaling pathway. We hypothesize that targeting PARPi induced senescence may provide a means to enhance the efficacy of PARPi treatment. In our current work, we sought to 1) understand whether senescence induction is a generalized response to all PARPi’s and 2) characterize senescence induction to guide the development of novel treatment strategies combining a PARPi with a senolytic drug.
Methods: PARPi sensitive LNCaP and C4-2B prostate tumor cells were treated with olaparib, rucaparib, niraparib, or talazoparib for 5 days to induce senescence. Both vehicle treated and quiescent cells (LNCaP and C4-2B cultured in FBS-low (0.2%) conditions) were used as controls. Cell viability, flow cytometry, and beta-galactosidase activity assays tested response to PARPi’s. Western blot was used to detect PARP activity, apoptosis, and DNA damage response. RNA-sequencing was performed to characterize senescence induced signaling alterations.
Results: We found that exposure to rucaparib, niraparib, and talazoparib all induce a robust G2/M arrested senescence response in LNCaP and C4-2B cells, suggesting that senescence induction is a class effect of PARPi’s. PARPi induced senescence is characterized by activation of the p53 signaling pathway and significantly increased expression of the cyclin-dependent kinase inhibitor p21. Furthermore, PARPi induced senescence is distinct from quiescence, suggesting that response to PARP inhibition is phenotypically different from a more general growth arrest. RNA-sequencing revealed several signaling changes associated with senescence which may provide novel treatment opportunities.
Conclusions: Senolytics are a class of drugs thought to specifically target senescent cells. Our results demonstrate that PARPi’s induce senescence. Future work will be directed at further characterizing PARPi induced senescence, leading to rationally selected senolytic drug combinations which may enhance the efficacy of PARPi therapy.
Citation Format: Alan P. Lombard, Wei Lou, Christopher P. Evans, Allen C. Gao. Characterizing senescence response to PARP inhibition may provide opportunities for enhanced efficacy through combinations with senolytic agents [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1850.
Collapse
Affiliation(s)
- Alan P. Lombard
- 1University of California, Davis, Health Campus, Sacramento, CA
| | - Wei Lou
- 1University of California, Davis, Health Campus, Sacramento, CA
| | | | - Allen C. Gao
- 1University of California, Davis, Health Campus, Sacramento, CA
| |
Collapse
|
7
|
Lombard AP, Armstrong CM, D'Abronzo LS, Ning S, Leslie AR, Sharifi M, Lou W, Evans CP, Dall'Era M, Chen HW, Chen X, Gao AC. Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer. Mol Cancer Ther 2022; 21:677-685. [PMID: 35086956 PMCID: PMC8983570 DOI: 10.1158/1535-7163.mct-21-0604] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 10/08/2021] [Accepted: 01/12/2022] [Indexed: 11/16/2022]
Abstract
PARP inhibition represents the dawn of precision medicine for treating prostate cancer. Despite this advance, questions remain regarding the use of PARP inhibitors (PARPi) for the treatment of this disease, including (i) how specifically do PARPi-sensitive tumor cells respond to treatment, and (ii) how does PARPi resistance develop? To address these questions, we characterized response to olaparib in sensitive LNCaP and C4-2B cells and developed two olaparib-resistant derivative cell line models from each, termed LN-OlapR and 2B-OlapR, respectively. OlapR cells possess distinct morphology from parental cells and display robust resistance to olaparib and other clinically relevant PARPis, including rucaparib, niraparib, and talazoparib. In LNCaP and C4-2B cells, we found that olaparib induces massive DNA damage, leading to activation of the G2-M checkpoint, activation of p53, and cell-cycle arrest. Furthermore, our data suggest that G2-M checkpoint activation leads to both cell death and senescence associated with p21 activity. In contrast, both LN-OlapR and 2B-OlapR cells do not arrest at G2-M and display a markedly blunted response to olaparib treatment. Interestingly, both OlapR cell lines harbor increased DNA damage relative to parental cells, suggesting that OlapR cells accumulate and manage persistent DNA damage during acquisition of resistance, likely through augmenting DNA repair capacity. Further impairing DNA repair through CDK1 inhibition enhances DNA damage, induces cell death, and sensitizes OlapR cells to olaparib treatment. Our data together further our understanding of PARPi treatment and provide a cellular platform system for the study of response and resistance to PARP inhibition.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Urologic Surgery, University of California, Davis, Davis, California
- UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California
| | - Cameron M Armstrong
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Leandro S D'Abronzo
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Shu Ning
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Amy R Leslie
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Masuda Sharifi
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Wei Lou
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Christopher P Evans
- Department of Urologic Surgery, University of California, Davis, Davis, California
- UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California
| | - Marc Dall'Era
- Department of Urologic Surgery, University of California, Davis, Davis, California
- UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California
| | - Hong-Wu Chen
- UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California
- Department of Biochemistry and Molecular Medicine, University of California, Davis, Davis, California
- VA Northern California Health Care System, Sacramento, California
| | - Xinbin Chen
- UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California
- School of Veterinary Medicine, University of California, Davis, Davis, California
| | - Allen C Gao
- Department of Urologic Surgery, University of California, Davis, Davis, California
- UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California
- VA Northern California Health Care System, Sacramento, California
| |
Collapse
|
8
|
Liu C, Armstrong CM, Ning S, Yang JC, Lou W, Lombard AP, Zhao J, Wu CY, Yu A, Evans CP, Tepper CG, Li PK, Gao AC. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene 2021; 40:5379-5392. [PMID: 34272475 PMCID: PMC8413131 DOI: 10.1038/s41388-021-01914-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2021] [Revised: 06/09/2021] [Accepted: 06/17/2021] [Indexed: 02/07/2023]
Abstract
Targeting androgen signaling with the second-generation anti-androgen drugs, such as enzalutamide (Enza), abiraterone (Abi), apalutamide (Apal), and darolutamide (Daro), is the mainstay for the treatment of castration-resistant prostate cancer (CRPC). While these treatments are effective initially, resistance occurs frequently. Continued expression of androgen receptor (AR) and its variants such as AR-V7 despite AR-targeted therapy contributes to treatment resistance and cancer progression in advanced CRPC patients. This highlights the need for new strategies blocking continued AR signaling. Here, we identify a novel AR/AR-V7 degrader (ARVib) and found that ARVib effectively degrades AR/AR-V7 protein and attenuates AR/AR-V7 downstream target gene expression in prostate cancer cells. Mechanistically, ARVib degrades AR/AR-V7 protein through the ubiquitin-proteasome pathway mediated by HSP70/STUB1 machinery modulation. ARVib suppresses HSP70 expression and promotes STUB1 nuclear translocation, where STUB1 binds to AR/AR-V7 and promotes its ubiquitination and degradation. ARVib significantly inhibits resistant prostate tumor growth and improves enzalutamide treatment in vitro and in vivo. These data suggest that ARVib has potential for development as an AR/AR-V7 degrader to treat resistant CRPC.
Collapse
Affiliation(s)
- Chengfei Liu
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA
| | - Cameron M Armstrong
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Shu Ning
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Joy C Yang
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Wei Lou
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Alan P Lombard
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Jinge Zhao
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
| | - Chun-Yi Wu
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA
- Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, CA, USA
| | - Aiming Yu
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA
- Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, CA, USA
| | - Christopher P Evans
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA
| | - Clifford G Tepper
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA
- Department of Biochemistry and Molecular Medicine, University of California Davis, Davis, CA, USA
| | - Pui-Kai Li
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH, USA
| | - Allen C Gao
- Department of Urologic Surgery, University of California Davis, Davis, CA, USA.
- UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA.
- VA Northern California Health Care System, Sacramento, CA, USA.
| |
Collapse
|
9
|
Lombard AP, Lou W, Armstrong CM, D'Abronzo LS, Ning S, Evans CP, Gao AC. Activation of the ABCB1-amplicon promotes cellular viability and resistance to docetaxel and cabazitaxel in castration-resistant prostate cancer. Mol Cancer Ther 2021; 20:2061-2070. [PMID: 34326198 DOI: 10.1158/1535-7163.mct-20-0983] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2020] [Revised: 03/15/2021] [Accepted: 06/15/2021] [Indexed: 11/16/2022]
Abstract
Docetaxel and cabazitaxel based taxane chemotherapy are critical components in the management of advanced prostate cancer. However, their efficacy is hindered due to de novo presentation with or the development of resistance. Characterizing models of taxane resistant prostate cancer will lead to creation of strategies to overcome insensitivity. We've previously characterized docetaxel resistant C4-2B and DU145 cell line derivatives, TaxR and DU145-DTXR, respectively. In the present study, we characterize cabazitaxel resistant derivative cell lines created from chronic cabazitaxel exposure of TaxR and DU145-DTXR cells, CabR and CTXR, respectively. We show that CabR and CTXR cells are robustly resistant to both taxanes but retain sensitivity to anti-androgens. Both CabR and CTXR cells possess increased expression of ABCB1, which is shown to mediate resistance to treatment. Interestingly, we also present evidence for coordinated overexpression of additional genes present within the 7q21.12 gene locus where ABCB1 resides. This locus, known as the ABCB1-amplicon, has been demonstrated to be amplified in multidrug resistant tumor cells, but little is known regarding its role in prostate cancer. We show that two ABCB1-amplicon genes other than ABCB1, RUNDC3B and DBF4, promote cellular viability and treatment resistance in taxane resistant prostate cancer models. We present evidence that coordinated amplification of ABCB1-amplicon genes is common in a subset of prostate cancer patients. These data together suggest that ABCB1-amplicon activation plays a critical role in taxane resistance.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Urologic Surgery, University of California, Davis
| | - Wei Lou
- Department of Urologic Surgery, University of California, Davis
| | | | | | - Shu Ning
- Urological Surgery, University of California, Davis
| | | | - Allen C Gao
- Department of Urologic Surgery, University of California, Davis
| |
Collapse
|
10
|
Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ, Platero AJ, Ma AH, Pan CX, Ghosh PM, Mudryj M. Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. Cancer Lett 2021; 504:49-57. [PMID: 33549708 DOI: 10.1016/j.canlet.2021.01.029] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 01/22/2021] [Accepted: 01/29/2021] [Indexed: 01/21/2023]
Abstract
Bladder cancer (BlCa) exhibits a gender disparity where men are three times more likely to develop the malignancy than women suggesting a role for the androgen receptor (AR). Here we report that BlCa cells express low molecular weight (LMW) AR isoforms that are missing the ligand binding domain (LBD). Isoform expression was detected in most BlCa cells, while a few express the full-length AR. Immunofluorescence studies detect AR in the nucleus and cytoplasm, and localization is cell dependent. Cells with nuclear AR expression exhibit reduced viability and increased apoptosis on total AR depletion. A novel AR-LMW variant, AR-v19, that is missing the LBD and contains 15 additional amino acids encoded by intron 3 sequences was detected in most BlCa malignancies. AR-v19 localizes to the nucleus and can transactivate AR-dependent transcription in a dose dependent manner. AR-v19 depletion impairs cell viability and promotes apoptosis in cells that express this variant. Thus, AR splice variant expression is common in BlCa and instrumental in ensuring cell survival. This suggests that targeting AR or AR downstream effectors may be a therapeutic strategy for the treatment of this malignancy.
Collapse
Affiliation(s)
- Kimberley Katleba
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA
| | - Alan P Lombard
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA; Biochemistry, Molecular, Cellular, and Developmental Biology Graduate Group and Biotechnology Program, USA
| | - Maria-Malvina Tsamouri
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Urologic Surgery, University of California, 1 Shields Avenue, UC Davis, Davis, CA, 95616, USA
| | - Han Bit Baek
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA
| | | | - Stephen J Libertini
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA
| | | | - Ai-Hong Ma
- Department of Urologic Surgery, University of California, 1 Shields Avenue, UC Davis, Davis, CA, 95616, USA
| | - Chong-Xian Pan
- Department of Faculty of Medicine, Harvard Medical School, West Roxbury, MA, 02115, USA
| | - Paramita M Ghosh
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Urologic Surgery, University of California, 1 Shields Avenue, UC Davis, Davis, CA, 95616, USA
| | - Maria Mudryj
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA.
| |
Collapse
|
11
|
Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, Ning S, Lombard AP, Zhao J, D'Abronzo LS, Evans CP, Li PK, Gao AC. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clin Cancer Res 2020; 26:6064-6074. [PMID: 32928794 DOI: 10.1158/1078-0432.ccr-20-1682] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Revised: 06/24/2020] [Accepted: 09/09/2020] [Indexed: 11/16/2022]
Abstract
PURPOSE Most patients with prostate cancer receiving enzalutamide or abiraterone develop resistance. Clinical evidence indicates that serum levels of dehydroepiandrosterone sulfate (DHEAS) and biologically active DHEA remain in the high range despite antiandrogen treatment. The conversion of DHEAS into DHEA by steroid sulfatase (STS) may contribute to sustained intracrine androgen synthesis. Here, we determine the contribution of STS to treatment resistance and explore the potential of targeting STS to overcome resistance in prostate cancer. EXPERIMENTAL DESIGN STS expression was examined in patients and cell lines. In vitro, STS activity and expression were modulated using STS-specific siRNA or novel STS inhibitors (STSi). Cell growth, colony formation, androgen production, and gene expression were examined. RNA-sequencing analysis was conducted on VCaP cells treated with STSi. Mice were treated with STSis with or without enzalutamide to determine their effects in vivo. RESULTS STS is overexpressed in patients with castration-resistant prostate cancer (CRPC) and resistant cells. STS overexpression increases intracrine androgen synthesis, cell proliferation, and confers resistance to enzalutamide and abiraterone. Inhibition of STS using siRNA suppresses prostate cancer cell growth. Targeting STS activity using STSi inhibits STS activity, suppresses androgen receptor transcriptional activity, and reduces the growth of resistant C4-2B and VCaP prostate cancer cells. STSis significantly suppress resistant VCaP tumor growth, decrease serum PSA levels, and enhance enzalutamide treatment in vitro and in vivo. CONCLUSIONS These studies suggest that STS drives intracrine androgen synthesis and prostate cancer proliferation. Targeting STS represents a therapeutic strategy to treat CRPC and improve second-generation antiandrogen therapy.
Collapse
Affiliation(s)
- Cameron M Armstrong
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Chengfei Liu
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Liangren Liu
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Joy C Yang
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Wei Lou
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Ruining Zhao
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Shu Ning
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Alan P Lombard
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Jinge Zhao
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Leandro S D'Abronzo
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Christopher P Evans
- Department of Urologic Surgery, University of California, Davis, Sacramento, California.,UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California
| | - Pui-Kai Li
- Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, Ohio
| | - Allen C Gao
- Department of Urologic Surgery, University of California, Davis, Sacramento, California. .,UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California.,VA Northern California Health Care System, Sacramento, California
| |
Collapse
|
12
|
Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP, D'Abronzo LS, Evans CP, Gao AC, Liu C. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Mol Cancer Ther 2020; 19:1708-1718. [PMID: 32430485 DOI: 10.1158/1535-7163.mct-20-0015] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2020] [Revised: 04/08/2020] [Accepted: 05/14/2020] [Indexed: 11/16/2022]
Abstract
The next-generation antiandrogen drugs, XTANDI (enzalutamide), ZYTIGA (abiraterone acetate), ERLEADA (apalutamide) and NUBEQA (darolutamide) extend survival times and improve quality of life in patients with advanced prostate cancer. Despite these advances, resistance occurs frequently and there is currently no definitive cure for castration-resistant prostate cancer. Our previous studies identified that similar mechanisms of resistance to enzalutamide or abiraterone occur following treatment and cross-resistance exists between these therapies in advanced prostate cancer. Here, we show that enzalutamide- and abiraterone-resistant prostate cancer cells are further cross-resistant to apalutamide and darolutamide. Mechanistically, we have determined that the AKR1C3/AR-V7 axis confers this cross-resistance. Knockdown of AR-V7 in enzalutamide-resistant cells resensitize cells to apalutamide and darolutamide treatment. Furthermore, targeting AKR1C3 resensitizes resistant cells to apalutamide and darolutamide treatment through AR-V7 inhibition. Chronic apalutamide treatment in C4-2B cells activates the steroid hormone biosynthesis pathway and increases AKR1C3 expression, which confers resistance to enzalutamide, abiraterone, and darolutamide. In conclusion, our results suggest that apalutamide and darolutamide share similar resistant mechanisms with enzalutamide and abiraterone. The AKR1C3/AR-V7 complex confers cross-resistance to second-generation androgen receptor-targeted therapies in advanced prostate cancer.
Collapse
Affiliation(s)
- Jinge Zhao
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Shu Ning
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Wei Lou
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Joy C Yang
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Cameron M Armstrong
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Alan P Lombard
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Leandro S D'Abronzo
- Department of Urologic Surgery, University of California, Davis, Sacramento, California
| | - Christopher P Evans
- Department of Urologic Surgery, University of California, Davis, Sacramento, California.,UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California
| | - Allen C Gao
- Department of Urologic Surgery, University of California, Davis, Sacramento, California. .,UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California.,VA Northern California Health Care System, Sacramento, California
| | - Chengfei Liu
- Department of Urologic Surgery, University of California, Davis, Sacramento, California. .,UC Davis Comprehensive Cancer Center, University of California, Davis, Sacramento, California
| |
Collapse
|
13
|
Siddiqui S, Libertini SJ, Lucas CA, Lombard AP, Baek HB, Nakagawa RM, Nishida KS, Steele TM, Melgoza FU, Borowsky AD, Durbin-Johnson BP, Qi L, Ghosh PM, Mudryj M. The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells. Cancer Lett 2020; 483:12-21. [PMID: 32330514 DOI: 10.1016/j.canlet.2020.03.030] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2019] [Revised: 02/29/2020] [Accepted: 03/28/2020] [Indexed: 02/08/2023]
Abstract
Prostate cancer (PCa) is characterized by a unique dependence on optimal androgen receptor (AR) activity where physiological androgen concentrations induce proliferation but castrate and supraphysiological levels suppress growth. This feature has been exploited in bipolar androgen therapy (BAT) for castrate resistant malignancies. Here, we investigated the role of the tumor suppressor protein p14ARF in maintaining optimal AR activity and the function of the AR itself in regulating p14ARF levels. We used a tumor tissue array of differing stages and grades to define the relationships between these components and identified a strong positive correlation between p14ARF and AR expression. Mechanistic studies utilizing CWR22 xenograft and cell culture models revealed that a decrease in AR reduced p14ARF expression and deregulated E2F factors, which are linked to p14ARF and AR regulation. Chromatin immunoprecipitation studies identified AR binding sites upstream of p14ARF. p14ARF depletion enhanced AR-dependent PSA and TMPRSS2 transcription, hence p14ARF constrains AR activity. However, p14ARF depletion ultimately results in apoptosis. In PCa cells, AR co-ops p14ARF as part of a feedback mechanism to ensure optimal AR activity for maximal prostate cancer cell survival and proliferation.
Collapse
Affiliation(s)
- Salma Siddiqui
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA
| | - Stephen J Libertini
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA
| | - Christopher A Lucas
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA
| | - Alan P Lombard
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA
| | - Han Bit Baek
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA
| | | | | | - Thomas M Steele
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Urologic Surgery, USA
| | - Frank U Melgoza
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA
| | | | | | - LiHong Qi
- Department of Public Health Sciences, University of California Davis, California, USA
| | - Paramita M Ghosh
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Urologic Surgery, USA
| | - Maria Mudryj
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA; Department of Medical Microbiology and Immunology, USA.
| |
Collapse
|
14
|
Abstract
The clinical landscape concerning advanced prostate cancer is rapidly changing and reaching beyond androgen deprivation therapy and androgen receptor targeted therapies. Taxane chemotherapy is a critical tool in the management of advanced prostate cancer. Additionally, novel drug classes such as PARP inhibitors are being investigated. Despite tremendous progress, resistance to therapy remains as a major impediment to further improvement. Resistance mechanisms appear diverse and are not fully known or understood. This review will highlight recent advances in research regarding mechanisms of resistance to both taxanes (such as increased drug efflux capacity) and PARP inhibitors (such as reversion mutations which restore DNA-repair proficiency). Understanding resistance to therapy promises to remove barriers blocking progress toward improved patient outcomes.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Urologic Surgery, University of California, Davis, CA, USA
| | - Allen C Gao
- Department of Urologic Surgery, University of California, Davis, CA, USA.,UC Davis Comprehensive Cancer Center, University of California, Davis, CA, USA.,VA Northern California Health Care System Sacramento, CA, USA
| |
Collapse
|
15
|
Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D'Abronzo LS, Evans CP, Gao AC. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Mol Cancer Ther 2019; 18:1875-1886. [PMID: 31308078 PMCID: PMC6995728 DOI: 10.1158/1535-7163.mct-18-1322] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Revised: 05/07/2019] [Accepted: 07/08/2019] [Indexed: 01/12/2023]
Abstract
The mechanisms resulting in resistance to next-generation antiandrogens in castration-resistant prostate cancer are incompletely understood. Numerous studies have determined that constitutively active androgen receptor (AR) signaling or full-length AR bypass mechanisms may contribute to the resistance. Previous studies established that AKR1C3 and AR-V7 play important roles in enzalutamide and abiraterone resistance. In the present study, we found that AKR1C3 increases AR-V7 expression in resistant prostate cancer cells through enhancing protein stability via activation of the ubiquitin-mediated proteasome pathway. AKR1C3 reprograms AR signaling in enzalutamide-resistant prostate cancer cells. In addition, bioinformatical analysis of indomethacin-treated resistant cells revealed that indomethacin significantly activates the unfolded protein response, p53, and apoptosis pathways, and suppresses cell-cycle, Myc, and AR/ARV7 pathways. Targeting AKR1C3 with indomethacin significantly decreases AR/AR-V7 protein expression in vitro and in vivo through activation of the ubiquitin-mediated proteasome pathway. Our results suggest that the AKR1C3/AR-V7 complex collaboratively confers resistance to AR-targeted therapies in advanced prostate cancer.
Collapse
Affiliation(s)
- Chengfei Liu
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Joy C Yang
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Cameron M Armstrong
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Wei Lou
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Liangren Liu
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Xiaomin Qiu
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Binhao Zou
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Alan P Lombard
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Leandro S D'Abronzo
- Department of Urologic Surgery, University of California, Davis, Davis, California
| | - Christopher P Evans
- Department of Urologic Surgery, University of California, Davis, Davis, California
- UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California
| | - Allen C Gao
- Department of Urologic Surgery, University of California, Davis, Davis, California.
- UC Davis Comprehensive Cancer Center, University of California, Davis, Davis, California
- VA Northern California Health Care System, Sacramento, California
| |
Collapse
|
16
|
Lombard AP, Liu C, Armstrong CM, D’Abronzo LS, Lou W, Evans CP, Gao AC. Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. Am J Clin Exp Urol 2019; 7:203-214. [PMID: 31511827 PMCID: PMC6734040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Accepted: 08/02/2019] [Indexed: 06/10/2023]
Abstract
BACKGROUND De-regulation of Wnt signaling pathways has been shown to be associated with progression of castration-resistant prostate cancer and more recently, studies indicate that both canonical and non-canonical Wnt pathways may mediate resistance to anti-androgen therapies such as enzalutamide. However, the mechanisms by which Wnt signaling is altered in prostate cancer remain poorly understood. Wnt pathway function begins with Wnt biogenesis and secretion from Wnt signal sending cells. While previous studies have investigated downstream mechanisms of Wnt pathway alterations in prostate cancer, little is known on the role of Wnt secretion mediating proteins. Wntless (WLS) is thought to be essential for the secretion of all Wnts. In this study, we sought to understand the role of WLS in prostate cancer. METHODS RNA-seq and gene set enrichment analysis were used to understand expression profile changes in enzalutamide-resistant C4-2B-MDVR (MDVR) cells versus parental C4-2B cells. Quantitative-PCR and western blot were used to confirm RNA-seq data and to assess expression changes of gene targets of interest. Rv1 cells were used as a separate model of enzalutamide-resistant prostate cancer. RNAi was used to inhibit WLS expression. Cell viability, colony formation, and PSA ELISA assays were used to assess cell growth and survival. RESULTS Transcriptomic profiling revealed enriched Wnt pathway signatures in MDVR versus parental C4-2B cells. We further show that MDVR cells upregulate Wnt signaling and overexpress WLS. Inhibition of WLS decreases Wnt signaling, markedly attenuates prostate cancer cell viability, induces apoptosis, and re-sensitizes enzalutamide-resistant cells to enzalutamide treatment. Lastly, we show that inhibition of WLS reduces AR and AR-variants expression and downstream signaling. CONCLUSIONS Our findings support a role for WLS in the progression of prostate cancer to a treatment-resistant state. Further efforts to understand Wnt signaling pathway alterations in this disease may lead to the development of novel treatments.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Urologic Surgery, University of California DavisCA, USA
| | - Chengfei Liu
- Department of Urologic Surgery, University of California DavisCA, USA
| | | | | | - Wei Lou
- Department of Urologic Surgery, University of California DavisCA, USA
| | - Christopher P Evans
- Department of Urologic Surgery, University of California DavisCA, USA
- UC Davis Comprehensive Cancer Center, University of California DavisCA, USA
| | - Allen C Gao
- Department of Urologic Surgery, University of California DavisCA, USA
- UC Davis Comprehensive Cancer Center, University of California DavisCA, USA
- VA Northern California Health Care SystemSacramento, CA, USA
| |
Collapse
|
17
|
Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, Gao AC. Abstract 1823: SNORD78 promotes prostate cancer progression and regulates AR expression and signaling. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-1823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
While small nucleolar RNAs (snoRNAs) have long been thought of as housekeeping genes, emerging evidence now suggests that snoRNAs are involved in more than previously thought and also in the development of disease. In cancer, it is understood that snoRNA expression and function can be altered, but little is known regarding the role of snoRNAs in these diseases. SNORD78 is a C/D box snoRNA which has been shown to be overexpressed in prostate cancer and associated with disease progression. However, there are no studies functionally characterizing SNORD78 in prostate cancer. In this study we sought to understand the functional contribution of SNORD78 in prostate cancer progression. Oncomine was used to assess SNORD78 expression in clinical prostate cancer samples. LNCaP and C4-2B prostate cancer cell lines were used. We used siRNAs to inhibit SNORD78 expression and cell viability assays to assess cell growth. ELISAs were used to assess PSA secretion and cell death. Western blots and quantitative PCR were used to assess cell death (PARP-cleavage) and AR expression and signaling. We found that SNORD78 expression was up-regulated in prostate tumors and associated with metastatic progression. Cell viability assays demonstrated that inhibition of SNORD78 expression resulted in a drastic reduction in prostate cancer cell growth and lower secretion of PSA into the media. Cell death ELISAs and western blots for cleaved-PARP showed that SNORD78 inhibition induced robust apoptosis in both LNCaP and C4-2B cells. As the androgen receptor (AR) is the primary target for prostate cancer therapy, we tested whether SNORD78 regulated AR expression and signaling. Inhibition of SNORD78 in both LNCaP and C4-2B cells resulted in reduced AR mRNA and protein levels. We also found that SNORD78 knockdown led to decreased levels of PSA and NKX3.1, suggesting that AR downstream signaling was inhibited. Our findings suggest that SNORD78 promotes prostate cancer cell viability and disease progression. We also demonstrate that SNORD78 regulates the AR and may be involved in promoting AR signaling needed for prostate cancer cell survival. Collectively, these data suggest that SNORD78 plays a critical role in prostate cancer progression and may represent a novel therapeutic target.
Citation Format: Alan P. Lombard, Chengfei Liu, Cameron M. Armstrong, Leandro S. D'Abronzo, Wei Lou, Christopher P. Evans, Allen C. Gao. SNORD78 promotes prostate cancer progression and regulates AR expression and signaling [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1823.
Collapse
Affiliation(s)
| | | | | | | | - Wei Lou
- UC Davis Medical Center, Sacramento, CA
| | | | | |
Collapse
|
18
|
Armstrong CM, Liu C, Lou W, Lombard AP, Evans C, Gao AC. Abstract 3030: HSD3B1 mediated anti-androgen resistance in prostate cancer requires specific androgen precursors. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Resistance to anti-androgens, such as enzalutamide (Enza) or abiraterone (Abi), develops within 24 months of initial exposure in most prostate cancer (PCa) patients. Commonly, dysregulated androgen signaling is a key feature of resistant disease. Previous studies demonstrate that androgen synthesis is upregulated in Enza and Abi resistance. HSD3B1 is steroidogenic enzyme which contributes to androgen synthesis and is associated with PCa progression. This study aims to determine the role of HSD3B1 in promoting Enza and Abi resistance in PCa.
Enza resistant (C4-2B MDVR) and Abi resistant (C4-2B AbiR) C4-2B PCa cells were generated by chronically exposing parental C4-2B cells to increasing Enza or Abi concentrations for >12 months. Cells were maintained in 20 µM Enza or 10 µM Abi thereafter. Microarray, RNA-seq, and rtPCR were used to determine differences in gene expression between parental and anti-androgen resistant cells and confirmed by Western blot. HSD3B1 expression was knocked down in C4-2B MDVR and C4-2B AbiR cells using shRNA and cell number was determined in media containing FBS, charcoal dextran stripped FBS (CDFBS), or CDFBS supplemented with 100 nM pregnenolone (P5), 100 nM DHEA, or 10 nM DHT in the presence and absence of 20 µM Enza or 10 µM Abi. PSA secretion was determined by ELISA and PSA-luciferase activity was measured by reporter assay.
C4-2B MDVR and C4-2B AbiR cells have increased HSD3B1 expression compared to parental C4-2B cells. This correlates to an increase in intracrine androgens in C4-2B MDVR cells as determined by LC-MS. Knockdown of HSD3B1 in C4-2B MDVR resensitized cells to Enza in FBS, CDFBS+DHT and CDFBS+P5 conditions as determined by a reduction in cell number and PSA secretion and/or PSA-luciferase activity in response to Enza. In the C4-2B AbiR cells, inhibition of HSD3B1 re-sensitized cells to treatment with Abi in FBS, CDFBS, and CDFBS+P5 conditions with the greatest effects seen in the FBS and CDFBS+P5 conditions. Supplementation with P5, but not DHEA, was able to induce PSA-luciferase activity and cell growth in C4-2B MDVR and C4-2B AbiR cells and this could be blocked by knockdown of HSD3B1.
HSD3B1 overexpression in C4-2B MDVR and C4-2B AbiR cells contributes to Enza and Abi resistance and targeting this enzyme could be a viable strategy to improve anti-androgen response in PCa cells. HSD3B1 activity is reliant on select androgen precursors, such as pregnenolone, indicating preference towards a specific androgen synthesis pathway by HSD3B1 in mediating anti-androgen resistance.
Citation Format: Cameron M. Armstrong, Chengfei Liu, Wei Lou, Alan P. Lombard, Christopher Evans, Allen C. Gao. HSD3B1 mediated anti-androgen resistance in prostate cancer requires specific androgen precursors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3030.
Collapse
Affiliation(s)
| | | | - Wei Lou
- UC Davis Medical Ctr., Sacramento, CA
| | | | | | | |
Collapse
|
19
|
Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol 2019; 12:871-878. [PMID: 31075528 PMCID: PMC6510951 DOI: 10.1016/j.tranon.2019.04.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Accepted: 04/10/2019] [Indexed: 12/13/2022] Open
Abstract
Castration-resistant prostate cancer remains as an incurable disease. Exploiting DNA damage repair defects via inhibition of poly (ADP-ribose) polymerase (PARP) is becoming an attractive therapeutic option. The TOPARP-A clinical trial demonstrated that the PARP inhibitor olaparib may be an effective strategy for treating prostate cancer. However, several unanswered questions regarding the use of olaparib remain: 1) How do we best stratify patients for olaparib treatment? 2) Where do we place olaparib in the treatment sequence paradigm? 3) Is there cross-resistance between olaparib and currently used therapies? Here, we tested putative cross-resistance between current therapies and olaparib in treatment-resistant castration-resistant prostate cancer models. Docetaxel-resistant cells exhibited robust resistance to olaparib which could be attributed to blunted PARP trapping in response to olaparib treatment. Upregulated ABCB1 mediates cross-resistance between taxanes and olaparib, which can be overcome through decreasing ABCB1 expression or inhibiting ABCB1 using elacridar or enzalutamide. We also show that combining olaparib with enzalutamide is more effective in olaparib-sensitive cells than either single agent. Our results demonstrate that cross-resistance between olaparib and other therapies could blunt response to treatment and highlight the need to develop strategies to maximize olaparib efficacy.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817
| | - Chengfei Liu
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817
| | - Cameron M Armstrong
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817
| | - Leandro S D'Abronzo
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817
| | - Wei Lou
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817
| | - Hongwu Chen
- Department of Biochemistry and Molecular Medicine, University of California Davis, 2700 Stockton Blvd, Suite 2102, Sacramento, CA 95817; UC Davis Comprehensive Cancer Center, University of California Davis, 2279 45(th) Street, Sacramento, CA 95817; VA Northern California Health Care System, Sacramento, 10535 Hospital Way, Mather, CA 95655
| | - Marc Dall'Era
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817; UC Davis Comprehensive Cancer Center, University of California Davis, 2279 45(th) Street, Sacramento, CA 95817
| | - Paramita M Ghosh
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817; UC Davis Comprehensive Cancer Center, University of California Davis, 2279 45(th) Street, Sacramento, CA 95817; VA Northern California Health Care System, Sacramento, 10535 Hospital Way, Mather, CA 95655
| | - Christopher P Evans
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817; UC Davis Comprehensive Cancer Center, University of California Davis, 2279 45(th) Street, Sacramento, CA 95817
| | - Allen C Gao
- Department of Urologic Surgery, University of California Davis, 4860 Y Street, Suite 2200, Sacramento, CA 95817; UC Davis Comprehensive Cancer Center, University of California Davis, 2279 45(th) Street, Sacramento, CA 95817; VA Northern California Health Care System, Sacramento, 10535 Hospital Way, Mather, CA 95655.
| |
Collapse
|
20
|
Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. Oncotarget 2018; 9:34567-34581. [PMID: 30349650 PMCID: PMC6195388 DOI: 10.18632/oncotarget.26179] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Accepted: 09/15/2018] [Indexed: 12/28/2022] Open
Abstract
Treatment options for high grade urothelial cancers are limited and have remained largely unchanged for several decades. Selinexor (KPT-330), a first in class small molecule that inhibits the nuclear export protein XPO1, has shown efficacy as a single agent treatment for numerous different malignancies, but its efficacy in limiting bladder malignancies has not been tested. In this study we assessed selinexor-dependent cytotoxicity in several bladder tumor cells and report that selinexor effectively reduced XPO1 expression and limited cell viability in a dose dependent manner. The decrease in cell viability was due to an induction of apoptosis and cell cycle arrest. These results were recapitulated in in vivo studies where selinexor decreased tumor growth. Tumors treated with selinexor expressed lower levels of XPO1, cyclin A, cyclin B, and CDK2 and increased levels of RB and CDK inhibitor p27, a result that is consistent with growth arrest. Cells expressing wildtype RB, a potent tumor suppressor that promotes growth arrest and apoptosis, were most susceptible to selinexor. Cell fractionation and immunofluorescence studies showed that selinexor treatment increased nuclear RB levels and mechanistic studies revealed that RB ablation curtailed the response to the drug. Conversely, limiting CDK4/6 dependent RB phosphorylation by palbociclib was additive with selinexor in reducing bladder tumor cell viability, confirming that RB activity has a role in the response to XPO1 inhibition. These results provide a rationale for XPO1 inhibition as a novel strategy for the treatment of bladder malignancies.
Collapse
Affiliation(s)
- Han Bit Baek
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA.,Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA
| | - Alan P Lombard
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA.,Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA.,Biochemistry, Molecular, Cellular, and Developmental Biology Graduate Group and Biotechnology Program, University of California Davis, Davis, CA, USA
| | - Stephen J Libertini
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA.,Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA
| | - Aleida Fernandez-Rubio
- Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA
| | - Ruth Vinall
- California Northstate College of Pharmacy, Elk Grove, CA, USA
| | - Regina Gandour-Edwards
- Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA, USA
| | - Rachel Nakagawa
- Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA
| | - Kathleen Vidallo
- Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA
| | - Kristine Nishida
- Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA
| | - Salma Siddiqui
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA
| | - Hiromi Wettersten
- Department of Internal Medicine, University of California Davis, Davis, CA, USA
| | | | - Robert H Weiss
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA.,Department of Internal Medicine, University of California Davis, Davis, CA, USA
| | - Paramita M Ghosh
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA.,Department of Urology, University of California Davis, Sacramento, CA, USA
| | - Maria Mudryj
- Veterans Affairs-Northern California Health Care System, Mather, CA, USA.,Department of Medical Microbiology and Immunology, University of California Davis, Davis, CA, USA
| |
Collapse
|
21
|
Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther 2018; 17:2197-2205. [PMID: 29891490 DOI: 10.1158/1535-7163.mct-17-1269] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2017] [Revised: 03/23/2018] [Accepted: 05/07/2018] [Indexed: 02/05/2023]
Abstract
Current treatments for castration resistant prostate cancer (CRPC) largely fall into two classes: androgen receptor (AR)-targeted therapies such as the next-generation antiandrogen therapies (NGAT), enzalutamide and abiraterone, and taxanes such as docetaxel and cabazitaxel. Despite improvements in outcomes, patients still succumb to the disease due to the development of resistance. Further complicating the situation is lack of a well-defined treatment sequence and potential for cross-resistance between therapies. We have developed several models representing CRPC with acquired therapeutic resistance. Here, we utilized these models to assess putative cross-resistance between treatments. We find that resistance to enzalutamide induces resistance to abiraterone and vice versa, but resistance to neither alters sensitivity to taxanes. Acquired resistance to docetaxel induces cross-resistance to cabazitaxel but not to enzalutamide or abiraterone. Correlating responses with known mechanisms of resistance indicates that AR variants are associated with resistance to NGATs, whereas the membrane efflux protein ABCB1 is associated with taxane resistance. Mechanistic studies show that AR variant-7 (AR-v7) is involved in NGAT resistance but not resistance to taxanes. Our findings suggest the existence of intra cross-resistance within a drug class (i.e., within NGATs or within taxanes), whereas inter cross-resistance between drug classes does not develop. Furthermore, our data suggest that resistance mechanisms differ between drug classes. These results may have clinical implications by showing that treatments of one class can be sequenced with those of another, but caution should be taken when sequencing similar classed drugs. In addition, the development and use of biomarkers indicating resistance will improve patient stratification for treatment. Mol Cancer Ther; 17(10); 2197-205. ©2018 AACR.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Urology, University of California, Davis, California
| | - Liangren Liu
- Department of Urology, University of California, Davis, California
- Department of Urology, West China Hospital, Sichuan University, Chengdu, China
| | - Vito Cucchiara
- Department of Urology, University of California, Davis, California
| | - Chengfei Liu
- Department of Urology, University of California, Davis, California
| | | | - Ruining Zhao
- Department of Urology, University of California, Davis, California
- Department of Urology, General Hospital of NingXia Medical University, Ningxia Huizuzizhiqu, China
| | - Joy C Yang
- Department of Urology, University of California, Davis, California
| | - Wei Lou
- Department of Urology, University of California, Davis, California
| | - Christopher P Evans
- Department of Urology, University of California, Davis, California
- UC Davis Comprehensive Cancer Center, University of California, Davis, California
| | - Allen C Gao
- Department of Urology, University of California, Davis, California.
- UC Davis Comprehensive Cancer Center, University of California, Davis, California
- VA Northern California Health Care System, Sacramento, California
| |
Collapse
|
22
|
Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Mol Cancer Ther 2017; 16:2257-2266. [PMID: 28698198 DOI: 10.1158/1535-7163.mct-17-0179] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2017] [Revised: 05/23/2017] [Accepted: 06/20/2017] [Indexed: 01/10/2023]
Abstract
Advancements in research have added several new therapies for castration-resistant prostate cancer (CRPC), greatly augmenting our ability to treat patients. However, CRPC remains an incurable disease due to the development of therapeutic resistance and the existence of cross-resistance between available therapies. Understanding the interplay between different treatments will lead to improved sequencing and the creation of combinations that overcome resistance and prolong survival. Whether there exists cross-resistance between docetaxel and the next-generation taxane cabazitaxel is poorly understood. In this study, we use C4-2B and DU145 derived docetaxel-resistant cell lines to test response to cabazitaxel. Our results demonstrate that docetaxel resistance confers cross-resistance to cabazitaxel. We show that increased ABCB1 expression is responsible for cross-resistance to cabazitaxel and that inhibition of ABCB1 function through the small-molecule inhibitor elacridar resensitizes taxane-resistant cells to treatment. In addition, the antiandrogens bicalutamide and enzalutamide, previously demonstrated to be able to resensitize taxane-resistant cells to docetaxel through inhibition of ABCB1 ATPase activity, are also able to resensitize resistant cells to cabazitaxel treatment. Finally, we show that resensitization using an antiandrogen is far more effective in combination with cabazitaxel than docetaxel. Collectively, these results address key concerns in the field, including that of cross-resistance between taxanes and highlighting a mechanism of cabazitaxel resistance involving ABCB1. Furthermore, these preclinical studies suggest the potential in using combinations of antiandrogens with cabazitaxel for increased effect in treating advanced CRPC. Mol Cancer Ther; 16(10); 2257-66. ©2017 AACR.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Urology, University of California Davis, Davis, California
| | - Chengfei Liu
- Department of Urology, University of California Davis, Davis, California
| | | | - Vito Cucchiara
- Department of Urology, University of California Davis, Davis, California
| | - Xinwei Gu
- Department of Urology, University of California Davis, Davis, California
| | - Wei Lou
- Department of Urology, University of California Davis, Davis, California
| | - Christopher P Evans
- Department of Urology, University of California Davis, Davis, California.,UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California
| | - Allen C Gao
- Department of Urology, University of California Davis, Davis, California. .,UC Davis Comprehensive Cancer Center, University of California Davis, Davis, California.,VA Northern California Health Care System, Sacramento, California
| |
Collapse
|
23
|
Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Prostate 2017; 77:1020-1028. [PMID: 28485104 PMCID: PMC5448975 DOI: 10.1002/pros.23358] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Accepted: 03/23/2017] [Indexed: 12/28/2022]
Abstract
BACKGROUND Docetaxel is one of the primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to docetaxel therapy and their disease will continue to progress. The mechanisms by which resistance develops are still incompletely understood. This study seeks to determine the involvement of miRNAs, specifically miR-181a, in docetaxel resistance in CRPC. METHODS Real-time PCR was used to measure miR-181a expression in parental and docetaxel resistant C4-2B and DU145 cells (TaxR and DU145-DTXR). miR-181a expression was modulated in parental or docetaxel resistant cells by transfecting them with miR-181a mimics or antisense, respectively. Following transfection, cell number was determined after 48 h with or without docetaxel. Cross resistance to cabazitaxel induced by miR-181a was also determined. Western blots were used to determine ABCB1 protein expression and rhodamine assays used to assess activity. Phospho-p53 expression was assessed by Western blot and apoptosis was measured by ELISA in C4-2B TaxR and PC3 cells with inhibited or overexpressed miR-181a expression with or without docetaxel. RESULTS miR-181a is significantly overexpressed in TaxR and DU145-DTXR cells compared to parental cells. Overexpression of miR-181a in parental cells confers docetaxel and cabazitaxel resistance and knockdown of miR-181a in TaxR cells re-sensitizes them to treatment with both docetaxel and cabazitaxel. miR-181a was not observed to impact ABCB1 expression or activity, a protein which was previously demonstrated to be highly involved in docetaxel resistance. Knockdown of miR-181a in TaxR cells induced phospho-p53 expression. Furthermore, miR-181a knockdown alone induced apoptosis in TaxR cells which could be further enhanced by the addition of DTX. CONCLUSIONS Overexpression of mir-181a in prostate cancer cells contributes to their resistance to docetaxel and cabazitaxel and inhibition of mir-181a expression can restore treatment response. This is due, in part, to modulation of p53 phosphorylation and apoptosis.
Collapse
Affiliation(s)
| | - Chengfei Liu
- Department of Urology, University of California Davis, CA, USA
| | - Wei Lou
- Department of Urology, University of California Davis, CA, USA
| | - Alan P. Lombard
- Department of Urology, University of California Davis, CA, USA
| | - Christopher P Evans
- Department of Urology, University of California Davis, CA, USA
- UC Davis Comprehensive Cancer Center, University of California Davis, CA, USA
| | - Allen C. Gao
- Department of Urology, University of California Davis, CA, USA
- UC Davis Comprehensive Cancer Center, University of California Davis, CA, USA
- VA Northern California Health Care System, Sacramento, CA, USA
| |
Collapse
|
24
|
Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther 2017; 16:1521-1530. [PMID: 28500234 DOI: 10.1158/1535-7163.mct-16-0912] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2016] [Revised: 02/28/2017] [Accepted: 04/27/2017] [Indexed: 11/16/2022]
Abstract
Activation of the androgen receptor (AR) and its splice variants is linked to advanced prostate cancer and drives resistance to antiandrogens. The roles of AR and AR variants in the development of resistance to androgen deprivation therapy (ADT) and bicalutamide treatment, however, are still incompletely understood. To determine whether AR variants play a role in bicalutamide resistance, we developed bicalutamide-resistant LNCaP cells (LNCaP-BicR) and found that these resistant cells express significantly increased levels of AR variants, particularly AR-V7, both at the mRNA and protein levels. Exogenous expression of AR-V7 in bicalutamide-sensitive LNCaP cells confers resistance to bicalutamide treatment. Knockdown of AR-V7 in bicalutamide- and enzalutamide-resistant CWR22Rv1, enzalutamide-resistant C4-2B (C4-2B MDVR), and LNCaP-BicR cells reversed bicalutamide resistance. Niclosamide, a potent inhibitor of AR variants, significantly enhanced bicalutamide treatment. Niclosamide and bicalutamide combination treatment not only suppressed AR and AR variants expression and inhibited their recruitment to the PSA promoter, but also significantly induced apoptosis in bicalutamide- and enzalutamide-resistant CWR22Rv1 and C4-2B MDVR cells. In addition, combination of niclosamide with bicalutamide inhibited the growth of enzalutamide-resistant tumors. In summary, our results demonstrate that AR variants, particularly AR-V7, drive bicalutamide resistance and that targeting AR-V7 with niclosamide can resensitize bicalutamide-resistant cells to bicalutamide treatment. Furthermore, combination of niclosamide with bicalutamide inhibits enzalutamide resistant tumor growth, suggesting that the combination of niclosamide and bicalutamide could be a potential cost-effective strategy to treat advanced prostate cancer in patients, including those who fail to respond to enzalutamide therapy. Mol Cancer Ther; 16(8); 1521-30. ©2017 AACR.
Collapse
Affiliation(s)
- Chengfei Liu
- Department of Urology, University of California Davis, California
| | | | - Wei Lou
- Department of Urology, University of California Davis, California
| | - Alan P Lombard
- Department of Urology, University of California Davis, California
| | - Vito Cucchiara
- Department of Urology, University of California Davis, California
| | - Xinwei Gu
- Department of Urology, University of California Davis, California
| | - Joy C Yang
- Department of Urology, University of California Davis, California
| | | | - Chong-Xian Pan
- Department of Medicine, University of California Davis, California.,UC Davis Comprehensive Cancer Center, University of California Davis, California.,VA Northern California Health Care System, Sacramento, California
| | - Christopher P Evans
- Department of Urology, University of California Davis, California.,UC Davis Comprehensive Cancer Center, University of California Davis, California
| | - Allen C Gao
- Department of Urology, University of California Davis, California. .,UC Davis Comprehensive Cancer Center, University of California Davis, California.,VA Northern California Health Care System, Sacramento, California
| |
Collapse
|
25
|
Abstract
Men are three to four times more likely to get bladder cancer than women. The gender disparity characterizing bladder cancer diagnoses has been investigated. One hypothesis is that androgen receptor (AR) signaling is involved in the etiology and progression of this disease. Although bladder cancer is not typically described as an endocrine-related malignancy, it has become increasingly clear that AR signaling plays a role in bladder tumors. This review summarizes current findings regarding the role of the AR in bladder cancer. We discuss work demonstrating AR expression in bladder cancer and its role in promoting formation and progression of tumors. Additionally, we discuss the therapeutic potential of targeting the AR in this disease.
Collapse
Affiliation(s)
- Alan P Lombard
- Veterans Affairs-Northern California Health Care System Mather, California, USA Department of Medical Microbiology and Immunology Biochemistry Molecular, Cellular, and Developmental Biology Graduate Group and Biotechnology Program, University of California, 1 Shields Avenue, Tupper Hall 3147, UC Davis, Davis, California 95616, USA Veterans Affairs-Northern California Health Care System Mather, California, USA Department of Medical Microbiology and Immunology Biochemistry Molecular, Cellular, and Developmental Biology Graduate Group and Biotechnology Program, University of California, 1 Shields Avenue, Tupper Hall 3147, UC Davis, Davis, California 95616, USA Veterans Affairs-Northern California Health Care System Mather, California, USA Department of Medical Microbiology and Immunology Biochemistry Molecular, Cellular, and Developmental Biology Graduate Group and Biotechnology Program, University of California, 1 Shields Avenue, Tupper Hall 3147, UC Davis, Davis, California 95616, USA
| | - Maria Mudryj
- Veterans Affairs-Northern California Health Care System Mather, California, USA Department of Medical Microbiology and Immunology Biochemistry Molecular, Cellular, and Developmental Biology Graduate Group and Biotechnology Program, University of California, 1 Shields Avenue, Tupper Hall 3147, UC Davis, Davis, California 95616, USA Veterans Affairs-Northern California Health Care System Mather, California, USA Department of Medical Microbiology and Immunology Biochemistry Molecular, Cellular, and Developmental Biology Graduate Group and Biotechnology Program, University of California, 1 Shields Avenue, Tupper Hall 3147, UC Davis, Davis, California 95616, USA
| |
Collapse
|
26
|
Mudryj M, Siddiqui S, Libertini SJ, Lombard AP, Mooso B, D'Abronzo L, Melgoza F, Borowsky A, Drake C, Qi L, Ghosh PM. Abstract 5051: Androgen receptor-mediated regulation of p14ARF transcription in prostate tumor cells. Cancer Res 2015. [DOI: 10.1158/1538-7445.am2015-5051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The p14ARF tumor suppressor is often deleted or silenced in malignancies. Prostate tumors are an exception, where p14 expression is elevated. To understand this phenomenon, we assessed the expression of p53 pathway members, which are most effected by p14ARF. The expression of androgen receptor (AR), a pivotal prostate cancer regulator, which is also affected by p14arf and MDM2 was analyzed as well. The studies used archival prostate tumor tissues obtained from prostatectomies performed at the Veterans Affairs-Northern California Health Care System in Mather California between 1996 and 2002 to better define the relationship between these interrelated networks. A prostate tumor tissue array consisting of 78 tumors of differing stages and grades was constructed to evaluate correlations between multiple parameters. Immunohistochemical studies assessed expression of the proliferation marker Ki67, p53, MDM2, MDM4, p14ARF, and the AR in the nuclear and cytoplasmic compartments of tumor and adjacent cells. p53, MDM4, p14ARF and AR were detected in nuclear and cytoplasmic compartments of tumor and non-tumor cells, but were predominantly nuclear. MDM2 expression was primarily cytoplasmic in tumor cells. Multivariate analysis of the immunohistochemical markers identified a strong correlation between expression of p14ARF and AR. Studies utilizing the prostate CWR22 xenograft and LNCaP cell line models revealed that castration or androgen deprivation resulted in reduced p14arf levels and that this effect correlated with a precipitous decline in E2F1-3a levels. In a reciprocal analysis, RB ablation enhanced p14ARF transcription, arguing that the E2F/RB pathway mediates AR-dependent p14ARF expression. However, we also identified an AR binding site located ∼40 KB upstream of the p14ARF gene. Chromatin immunoprecipitation (ChIP) studies showed that in prostate cells this site was bound by AR. ChIP studies also revealed E2F1 and E2F3 were present at the p14ARF promoter. Together, the studies argue p14ARF is a direct transcriptional target of AR and that AR and E2F collaborate to promote p14ARF expression.
.
Citation Format: Maria Mudryj, Salma Siddiqui, Stephen J. Libertini, Alan P. Lombard, Benjamin Mooso, Leandro D'Abronzo, Frank Melgoza, Alexander Borowsky, Christiana Drake, LiHong Qi, Paramita M. Ghosh. Androgen receptor-mediated regulation of p14ARF transcription in prostate tumor cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5051. doi:10.1158/1538-7445.AM2015-5051
Collapse
Affiliation(s)
| | - Salma Siddiqui
- 2Veterans Affairs-Northern California Health Care System, Mather, CA
| | | | | | - Benjamin Mooso
- 2Veterans Affairs-Northern California Health Care System, Mather, CA
| | | | - Frank Melgoza
- 2Veterans Affairs-Northern California Health Care System, Mather, CA
| | | | | | - LiHong Qi
- 1UC Davis School of Medicine, Davis, CA
| | | |
Collapse
|
27
|
Lombard AP, Lim RM, Nakagawa RM, Vidallo KD, Libertini SJ, Platero AJ, Mudryj M. Dicer ablation promotes a mesenchymal and invasive phenotype in bladder cancer cells. Oncol Rep 2015; 34:1526-32. [PMID: 26166215 DOI: 10.3892/or.2015.4117] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2015] [Accepted: 03/16/2015] [Indexed: 11/06/2022] Open
Abstract
Dicer expression is frequently altered in cancer and affects a wide array of cellular functions acting as an oncogene or tumor suppressor in varying contexts. It has been shown that Dicer expression is also deregulated in urothelial cell carcinoma of the bladder (UCCB) but the nature of this deregulation differs between reports. The aim of the present study was to gain a better understanding of the role of Dicer in bladder cancer to help determine its contribution to the disease. The results showed that Dicer transcript levels were decreased in UCCB tumor tissues as compared to normal tissues, suggesting that Dicer is a tumor suppressor. However, consistent with previous results, we demonstrated that knockdown of Dicer decreases cell viability and increases the induction of apoptosis, suggesting that Dicer is an oncogene. To resolve this discrepancy, we assessed the effects of decreased Dicer expression on epithelial-to‑mesenchymal transition, migration and invasion. We showed that decreased Dicer levels promoted a mesenchymal phenotype and increased migration. Additionally, the results showed that Dicer protein ablation leads to increased cell invasion, higher levels of matrix metalloproteinase-2, and decreased levels of key miRNAs shown to inhibit invasion. The results of this study suggest that decreased Dicer levels may portend a more malignant phenotype.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA
| | - Rebecca M Lim
- Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA
| | - Rachel M Nakagawa
- Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA
| | - Kathleen D Vidallo
- Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA
| | - Stephen J Libertini
- Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA
| | - Alexander J Platero
- Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA
| | - Maria Mudryj
- Department of Medical Microbiology and Immunology, University of California, Davis, CA, USA
| |
Collapse
|
28
|
Lombard AP, Mooso BA, Libertini SJ, Lim RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM, Mudryj M. miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1. Mol Carcinog 2015; 55:757-67. [PMID: 25865490 DOI: 10.1002/mc.22319] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Revised: 02/24/2015] [Accepted: 03/05/2015] [Indexed: 12/13/2022]
Abstract
Urothelial cell carcinoma of the bladder (UCCB) is the most common form of bladder cancer and it is estimated that ~15,000 people in the United States succumbed to this disease in 2013. Bladder cancer treatment options are limited and research to understand the molecular mechanisms of this disease is needed to design novel therapeutic strategies. Recent studies have shown that microRNAs play pivotal roles in the progression of cancer. miR-148a has been shown to serve as a tumor suppressor in cancers of the prostate, colon, and liver, but its role in bladder cancer has never been elucidated. Here we show that miR-148a is down-regulated in UCCB cell lines. We demonstrate that overexpression of miR-148a leads to reduced cell viability through an increase in apoptosis rather than an inhibition of proliferation. We additionally show that miR-148a exerts this effect partially by attenuating expression of DNA methyltransferase 1 (DNMT1). Finally, our studies demonstrate that treating cells with both miR-148a and either cisplatin or doxorubicin is either additive or synergistic in causing apoptosis. These data taken together suggest that miR-148a is a tumor suppressor in UCCB and could potentially serve as a novel therapeutic for this malignancy.
Collapse
Affiliation(s)
- Alan P Lombard
- Department of Medical Microbiology and Immunology, University of California, Davis, California.,Biochemistry, Molecular, Cellular, and Developmental Biology Graduate Group and Biotechnology Program, University of California, Davis, California.,Veterans Affairs-Northern California Health Care System, Mather, California
| | - Benjamin A Mooso
- Veterans Affairs-Northern California Health Care System, Mather, California
| | - Stephen J Libertini
- Department of Medical Microbiology and Immunology, University of California, Davis, California.,Veterans Affairs-Northern California Health Care System, Mather, California
| | - Rebecca M Lim
- Department of Medical Microbiology and Immunology, University of California, Davis, California
| | - Rachel M Nakagawa
- Department of Medical Microbiology and Immunology, University of California, Davis, California
| | - Kathleen D Vidallo
- Department of Medical Microbiology and Immunology, University of California, Davis, California
| | - Nicole C Costanzo
- Department of Medical Microbiology and Immunology, University of California, Davis, California
| | - Paramita M Ghosh
- Veterans Affairs-Northern California Health Care System, Mather, California.,Department of Urology, University of California, Davis, California
| | - Maria Mudryj
- Department of Medical Microbiology and Immunology, University of California, Davis, California.,Veterans Affairs-Northern California Health Care System, Mather, California
| |
Collapse
|
29
|
Mudryj M, Libertini SJ, Lombard AP, Saddiqui S, Ghosh PM. Abstract 2124: Analysis of FAM111A, a newly identified AR regulated gene, in prostate cancer. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-2124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Prostate carcinoma (PCa) is the most commonly diagnosed cancer in men in the United States. Most PCas are dependent on the androgen receptor (AR) for growth and survival, and this dependency is exploited as androgen deprivation is the major therapeutic intervention. However, PCa inevitably progress to become castration resistant, yet remain reliant on the activity of the AR. Further understanding the mechanisms that mediate castration resistance and the pathways downstream of the AR will enhance our ability to treat this stage of the disease. RNA-seq studies of two castrate resistant cell lines following AR ablation identified a number of transcripts that were AR regulated. The studies identified FAM111A as an AR regulated gene. While little is known about FAM111A, a previous study has shown that the FAM111A gene harbors a PCa susceptibility SNP and that the FAM111A protein interacts with SV40 T-Ag. Our studies indicate that AR represses FAM111A in cell culture and xenograft models of CaP. Additionally, the expression of the only known FAM111A paralogue, FAM111B, was reciprocally regulated in cell lines and in the xenograft. FAM111A is expressed in all cultured prostate derived cell lines we looked at, and we found that there are two FAM111A isoforms. Furthermore, a siRNA mediated ablation of FAM111A modified apoptotic responses to chemotherapeutic stimuli. An immunohistochemical analysis of a prostate tumor tissue array was used to assess the expression of FAM111A. FAM111A is expressed in the cytoplasmic and nuclear compartments and expression in the cytoplasmic compartment in non-tumor prostate tissue is higher than in adjacent tumor cells. In conclusions, FAM111a is an AR regulated gene, has been associated with PCa in a GWAS study, interacts with the SV40 T-antigen and is expressed at lower levels in tumor cells. This suggests that FAM111A may be have a role in prostate tumorigenesis.
Citation Format: Maria Mudryj, Stephen J. Libertini, Alan P. Lombard, Salma Saddiqui, Paramita M. Ghosh. Analysis of FAM111A, a newly identified AR regulated gene, in prostate cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2124. doi:10.1158/1538-7445.AM2014-2124
Collapse
Affiliation(s)
| | | | | | - Salma Saddiqui
- 2Veterans Affairs-Northern California Health Care System, Mather, CA
| | | |
Collapse
|
30
|
Lombard AP, Libertini S, Costanzo N, Lim R, Mudryj M. Abstract B226: MiR-148a dependent apoptosis of bladder cancer cells is mediated by the epigenetic modifier DNMT1. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-b226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: MiRNAs are now recognized as major players in cancer. MiR-148a has been shown to be a tumor suppressor in the context of several cancers including prostate, gastric, and lung but a study investigating its role in bladder cancer has never been performed. Here we sought to characterize the expression and role of miR-148a in bladder cancer.
Methods: Real time PCR was used to assess the levels of miR-148a across several bladder cancer cell lines. MiR-148a mimics were employed in T24 and UM-UC-3 cells to assess proliferation by CCK-8 proliferation assay, colony formation assay, and flow cytometry. Mimics were also used to assess apoptosis by immunoblot and annexin-V staining. SiRNA was used to knock-down DNMT1 to phenocopy miR-148a treatment. CCK-8 proliferation assays and crystal violet staining were used to assess the effects of miR-148a added to either cisplatin or doxorubicin on T24 and UM-UC-3 cells.
Results: All bladder cancer cell lines had significantly reduced expression of miR-148a than that of a control immortalized urothelial cell line. MiR-148a mimic treatment of T24 and UM-UC-3 cells lead to large decreases in viability. Flow cytometry demonstrated an S-phase arrest in miR-148a mimic treated cells versus control oligo treated cells. Immunoblots for cleaved caspase-3 and cleaved PARP along with annexin-V staining showed strong induction of apoptosis in miR-148a mimic treated cells. MiR-148a was shown to target DNMT1 and DNMT1 knock-down was able to phenocopy results from miR-148a mimic treatment suggesting DNMT1 is downstream of miR-148a. Finally, we found that miR-148a can be used with either cisplatin or doxorubicin for an additive effect in inducing apoptosis.
Conclusions: Our work demonstrates for the first time that miR-148a plays a tumor suppressive role in bladder cancer and suggests it could be used as a novel therapeutic agent either alone or in conjunction with chemotherapeutics.
Citation Information: Mol Cancer Ther 2013;12(11 Suppl):B226.
Citation Format: Alan P. Lombard, Steve Libertini, Nicole Costanzo, Rebecca Lim, Maria Mudryj. MiR-148a dependent apoptosis of bladder cancer cells is mediated by the epigenetic modifier DNMT1. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr B226.
Collapse
|
31
|
Mudryj M, Libertini SJ, Lombard AP. Abstract 3574: Studies of castrate resistant 22Rv1 cells identifies AR regulated interrelated networks of transcription factors, co-regulators, chromatin, and nuclear scaffolding proteins. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-3574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Prostate cancer development, progression and acquisition of castrate resistance are reliant on the activity of the androgen receptor (AR), a transcription factor that governs the proliferation of prostate cancer cells. Multiple studies have focused on the principle components that are critical for cell cycle transversal and these studies have identified members of the E2F/RB family, c-Myc, cyclins and cyclin dependent kinase inhibitors as key proteins that are instrumental in prostate cell proliferation and development of castrate resistance. But the mechanism by which the AR dominates this process is unclear. To identify the link between the AR and cell cycle control we used 22Rv1 cells which are castrate resistant due to the expression of low molecular weight AR forms that are missing the ligand binding domain. However, a siRNA mediated decrease in AR expression induces a growth arrest confirming that proliferation is AR dependent. RNA-seq analysis of gene expression at castrate levels of androgen and following AR ablation identified transcripts that were AR dependent. This methodology reduced the number of AR regulated transcripts, by excluding transcripts regulated by super-physiological levels of androgens. The AR regulated transcripts included previously identified genes (PMEPA1, C1orf116, PCDH7, APP) including NFAT a gene shown to be regulated by a low molecular weight AR isoform. The analysis also revealed that interrelated networks of transcription factors and co-factors were AR transactivated or repressed. These included proteins such as the LBR, LMNB, TMPO and SATB1 that do not directly promote transcription, but rather link chromatin to the nuclear membrane or scaffolding, suggesting that the AR may modulate gene expression through epigenetics mechanisms. Network analysis showed connections between these proteins and cell cycle components including E2Fs and Myc where a number of the regulated transcripts are known E2F or Myc targets. In addition, this analysis identified a number of non-coding RNAs; some that have been previously described and some that have yet to be annotated. qPCR studies found that a number of the transcripts regulated in 22Rv1 cells are also AR regulated in LNCaP cells. Coupled with ChIP-seq data, the study characterizes the link between the AR and the cell cycle machinery and chromatin modulating proteins.
Citation Format: Maria Mudryj, Stephen J. Libertini, Alan P. Lombard. Studies of castrate resistant 22Rv1 cells identifies AR regulated interrelated networks of transcription factors, co-regulators, chromatin, and nuclear scaffolding proteins. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3574. doi:10.1158/1538-7445.AM2013-3574
Collapse
Affiliation(s)
- Maria Mudryj
- Veterans Affairs-Northern California Health Care System, Mather, CA
| | | | - Alan P. Lombard
- Veterans Affairs-Northern California Health Care System, Mather, CA
| |
Collapse
|
32
|
Libertini SJ, Mudryj M, Lombard AP, Chen H, Rodriguez V, Perez-Stable C, al-Bataina B, Koilvaram T, George M, Gao AC. Abstract B47: Identification of novel E2F3 transcriptional targets expands the role of the RB/E2F axis beyond cell cycle control. Cancer Res 2012. [DOI: 10.1158/1538-7445.prca2012-b47] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The RB/E2F axis is frequently disrupted in multiple tumors. Classical studies reported that the RB tumor suppressor exerts its transcriptional repressor function through an interaction with the E2F family of transcription factors (E2F1-3) to control the timely expression of genes required for DNA replication and cell cycle progression. The E2F3 locus encodes two E2F3 isoforms, a and b, which have unique N-terminal sequences. Multiple studies indicate that E2F3, rather than E2F1 or 2, is elevated in various cancers, including prostate. In prostate tumors elevated E2F3 expression is an independent prognostic factor of clinical outcome, but the direct transcriptional targets of E2F3a and E2F3b have not been characterized. We found that E2F3a and b expression was increased in prostate tumor derived cell lines when compared to non-transformed controls. An expression array analysis following knockdown (k/d) of total E2F3 identified several unexpected targets including Interleukin 6 receptor (IL-6R), a critical component of the IL6 signaling cascade and calpain 2, a protease that is essential in cellular migration and has been shown to be elevated during prostate tumorigenesis. Further studies showed that the two genes were regulated by different E2F3 isoforms- IL6R was a target of E2F3a, while calpain 2 was regulated by E2F3b. Expression of both genes was enhanced by RB ablation. E2F3a-dependent IL-6R regulation was apparent in PC3, LNCaP, CWR-R1, and 22Rv1 cells. Chromatin immunoprecipitation (ChIP) studies identified sequences in the IL-6R promoter that were bound by E2F3. Transient co-transfection studies using an E2F3a expression plasmid showed that E2F3a transactivated the IL-6R promoter in a dose dependent manner. The IL-6R initiated signaling cascade was perturbed following a k/d of E2F3a since the levels of ERK1/2 phosphorylation was reduced. An siRNA-mediated ablation of each isoform revealed that E2F3b, not E2Fa, was effective is reducing calpain 2 levels. ChIP studies indicated that E2F3 binds to the endogenous calpain 2 promoter, and in transient transfection studies E2F3b transactivated the calpain 2 promoter in a dose dependent manner. An analysis of the calpain 2 promoter identified an androgen receptor (AR) half site. Additional transfection studies showed that the AR can cooperate with E2F3b in transactivation of the calpain 2 promoter. Moreover, reduced expression of E2F3b impaired cellular migration in a wound assay. The expression of the E2F3 isoforms has not been previously analyzed in the TRAMP prostate tumor model. Western immunoblot studies of five TRAMP tumors and three age and strain matched prostates showed that TRAMP tumors had highly elevated expression of both E2F3 isoforms. These results indicate that increased expression of both E2F3 isoforms is a feature of human tumor-derived cell lines and the TRAMP mouse model of prostate tumorigenesis. Calpain 2, expression was readily detected in all of the TRAMP tumors, but not in the control tissue. Hence E2F3 overexpression and increased calpain levels are features of human and mouse tumors. This analysis broadens the role of E2F3 in prostate tumorigenesis beyond the regulation of cell cycle progression. E2F3a is a link between the E2F/RB and the IL-6 signaling cascade, while E2F3b regulates expression of a protease that is essential in cell adhesion and migration. Therefore E2F3 deregulation affects multiple signaling networks to promote tumorigenesis.
Citation Format: Stephen J. Libertini, Maria Mudryj, Alan P. Lombard, Honglin Chen, Veronica Rodriguez, Carlos Perez-Stable, Bushra al-Bataina, Tilak Koilvaram, Michael George, Allen C. Gao. Identification of novel E2F3 transcriptional targets expands the role of the RB/E2F axis beyond cell cycle control [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr B47.
Collapse
Affiliation(s)
- Stephen J. Libertini
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Maria Mudryj
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Alan P. Lombard
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Honglin Chen
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Veronica Rodriguez
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Carlos Perez-Stable
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Bushra al-Bataina
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Tilak Koilvaram
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Michael George
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| | - Allen C. Gao
- 1Veterans Affairs-Northern California Health Care System, Mather, CA, 2University of California, Davis, CA, 3Veterans Affairs Medical Center, Miami, FL
| |
Collapse
|